Background The Ebola epidemic and COVID-19 pandemic disrupted essential healthcare services globally, including family planning, but the extent of disruptions in Sierra Leone is largely unknown. This study aimed to evaluates the impact of these crises on the uptake of contraceptive methods—short-acting contraceptives (SAC) and long-acting reversible contraceptives (LARC)— among adolescent girls and women ages 10-45 years in Sierra Leone from 2013 to 2022.

Methods We conducted a retrospective, cross-sectional study using aggregated DHIS2 data from adolescent girls and women aged 10-45 years. We describe and visualize the trends in the uptake of SAC and LARC before Ebola (March 2013 to April 2014), during Ebola (May 2014 to February 2016), after Ebola and before COVID-19 (March 2016 to February 2020), and during COVID-19 (March 2020 to February 2022). Proportional shifts and age-specific patterns were assessed to identify changes in contraceptive preferences.

Results During the Ebola outbreak (2014–2016), SAC uptake declined temporarily while LARC uptake modestly increased. A recovery in SAC uptake followed during the inter-epidemic period (2016–2019). Conversely, the COVID-19 pandemic (2020–2022) saw an initial spike in SAC uptake, which subsequently returned to pre-pandemic levels. In contrast, LARC uptake consistently increased throughout both pandemics and the post-pandemic period. Notably, a proportional shift toward LARC methods was observed. Trends across age groups were variable, with adolescents demonstrating resilience in their use of contraceptives during the COVID-19 pandemic.

Conclusion LARC services demonstrated remarkable stability during health emergencies, underscoring the resilience of long-term methods and the adaptability of women in making informed choices about their reproductive health amidst disruptions. These findings highlight the importance of strengthening healthcare systems to ensure continued access to reliable contraceptive options, particularly during crises.

The authors have declared no competing interest.

This study was conducted with support from the Canadian Institute of Health Research (WI1-179883).

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Ethics approval was obtained from the Sierra Leone Ethics and Scientific Review Committee of the Ministry of Health (approval number 015/05/2023). Secondary data were abstracted under a waiver of informed consent, and the research team did not have access to information that could identify individual participants during or after data collection.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes